Press & News

Press & News2020-02-25T19:19:07+00:00

Latest Articles

Browse a selection of ImaginAb press and news below.

2509, 2019

ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going “Base Line/On Therapy” (BOT) Phase II Clinical Trial

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). This study is a collaboration between UAB’s Division of Hematology and Oncology and Division of Molecular Imaging and Therapeutics, reflecting UAB’s commitment to world-class research and clinical care.

409, 2019

ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and/or present at the following investor and scientific conferences in September and October 2019: Word Molecular Imaging Congress, ESMO Congress, Cavendish Global Conference: The 2019 Phoenix BioHealth Impact Forum, 2nd Annual Advances in Immuno-Oncology USA Congress, and Optimum 11th Annual Healthcare Investor Conference.

907, 2019

ImaginAb Announces Collaboration on CD8 Imaging Agent with Roche

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics.

2006, 2019

ImaginAb to Present at SNMMI 2019 Annual Meeting

ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it will attend and present at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held June 22-25, 2019, at the Anaheim Convention Center, Anaheim, California.

Load More Posts